HomeInsightsStock Comparison

Beta Drugs Ltd vs Zydus Lifesciences Ltd Stock Comparison

Beta Drugs Ltd vs Zydus Lifesciences Ltd Stock Comparison

Last Updated on: Jun 06, 2025

Key Highlights

  • The Latest Trading Price of Beta Drugs Ltd is ₹ 1832 as of 06 Jun 15:40.
  • The P/E Ratio of Beta Drugs Ltd changed from 4.1 on March 2020 to 32.5 on March 2024 . This represents a CAGR of 51.29% over 5 yearsThe P/E Ratio of Zydus Lifesciences Ltd changed from 23.3 on March 2020 to 26.2 on March 2024 . This represents a CAGR of 2.37% over 5 years.
  • The Market Cap of Beta Drugs Ltd changed from ₹ 38.46 crore on March 2020 to ₹ 1186 crore on March 2024 . This represents a CAGR of 98.53% over 5 yearsThe Market Cap of Zydus Lifesciences Ltd changed from ₹ 27344 crore on March 2020 to ₹ 101151 crore on March 2024 . This represents a CAGR of 29.90% over 5 years.
  • The revenue of Beta Drugs Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Zydus Lifesciences Ltd for the Mar '25 is ₹ 6608 crore as compare to the Dec '24 revenue of ₹ 5326 crore. This represent the growth of 24.07%.
  • The ebitda of Beta Drugs Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Zydus Lifesciences Ltd for the Mar '25 is ₹ 1986 crore as compare to the Dec '24 ebitda of ₹ 1444 crore. This represent the growth of 37.49%.
  • The net profit of Beta Drugs Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Zydus Lifesciences Ltd changed from ₹ 1112 crore to ₹ 1248 crore over 8 quarters. This represents a CAGR of 5.97% .
  • The Dividend Payout of Beta Drugs Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Zydus Lifesciences Ltd changed from 25.37 % on March 2020 to 8.77 % on March 2024 . This represents a CAGR of -19.14% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Beta Drugs Ltd

  • Beta Drugs Limited was incorporated as a private limited company with the name 'Beta Drugs Private limited' at Himachal Pradesh on September 21, 2005.
  • Subsequently, the company was converted in to public limited company and the name of the company was changed to 'Beta Drugs Limited' on August 11, 2017 Beta Drugs is a part of Adley Group.
  • Adley Group was founded in the year 1985, by its promoter Vijay Batra, who has more than twenty five years of experience in manufacture of pharmaceutical products in India.
  • The Company is a pharmaceutical formulation manufacturing company engaged in developing, manufacturing and marketing of drug products for domestic and international customers.
  • The Promoter Vijay Batra, took over the company from Kiran Goyal, Deepak Kumar Prince Bharti and Rohit Bansal in the year 2014.

About Zydus Lifesciences Ltd

  • Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited) is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain including innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), Active Pharmaceutical Ingredients (APIs), animal healthcare products and consumer wellness products.
  • The Company operate manufacturing facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in Maharashtra and Solan in Himachal Pradesh. Founded by the Late Promoter, Mr. Ramanbhai B. Patel, the Company was incorporated in May, 1995 and converted into a Public Limited Company in July, 1996.

Beta Drugs Ltd News Hub

News

Beta Drugs to conduct board meeting

Beta Drugs will hold a meeting of the Board of Directors of the Company on 15 May 2025. Po...

Read more

10 May 2025 10:59

News

Beta Drugs announces board meeting date

Beta Drugs will hold a meeting of the Board of Directors of the Company on 27 March 2025. ...

Read more

20 Mar 2025 14:34

News

Beta Drugs to conduct board meeting

Beta Drugs will hold a meeting of the Board of Directors of the Company on 5 February 2025...

Read more

03 Feb 2025 10:49

News

Beta Drugs schedules EGM

Beta Drugs announced that an Extra Ordinary General Meeting (EGM) of the Company will be h...

Read more

28 Nov 2024 15:41

News

Beta Drugs to conduct board meeting

Beta Drugs will hold a meeting of the Board of Directors of the Company on 6 November 2024...

Read more

04 Nov 2024 14:01

News

Beta Drugs to conduct EGM

Beta Drugs announced that an Extra Ordinary General Meeting (EGM) of the Company will be h...

Read more

21 Oct 2024 13:59

Zydus Lifesciences Ltd News Hub

News

Zydus Lifesciences receives USFDA tentative approval for Rifaximin Tablets

Zydus Lifesciences has received tentative approval from the United States Food and Drug Ad...

Read more

02 Jun 2025 09:12

News

Zydus Lifesciences gets USFDA nod for Rifaximin tablets

Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrho...

Read more

02 Jun 2025 10:47

News

Zydus Lifesciences' Usnoflast receives USFDA fast track designation for ALS Treatment

The fast track designation is designed to facilitate the development and expedite the revi...

Read more

28 May 2025 13:23

News

Zydus Life gets USFDA nod for Isotretinoin capsules

The approved drug is the generic equivalent of the reference listed drug Absorica capsules...

Read more

26 May 2025 08:31

News

Zydus Lifesciences receives USFDA approval for Isotretinoin capsules

Zydus Lifesciences has received final approval from the United States Food and Drug Admini...

Read more

23 May 2025 18:05

News

Zydus Lifesciences to convene AGM

Zydus Lifesciences announced that the Annual General Meeting(AGM) of the company will be h...

Read more

22 May 2025 10:18

SWOT Analysis Of Zydus Lifesciences Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

2

T

SWOT Analysis Of Beta Drugs Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Zydus Lifesciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Beta Drugs Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Beta Drugs Ltd and Zydus Lifesciences Ltd

Which company has a larger market capitalization, Beta Drugs Ltd or Zydus Lifesciences Ltd?

Market cap of Beta Drugs Ltd is 1,846 Cr while Market cap of Zydus Lifesciences Ltd is 96,155 Cr

What are the key factors driving the stock performance of Beta Drugs Ltd and Zydus Lifesciences Ltd?

The stock performance of Beta Drugs Ltd and Zydus Lifesciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Beta Drugs Ltd and Zydus Lifesciences Ltd?

As of June 6, 2025, the Beta Drugs Ltd stock price is INR ₹1829.5. On the other hand, Zydus Lifesciences Ltd stock price is INR ₹955.6.

How do dividend payouts of Beta Drugs Ltd and Zydus Lifesciences Ltd compare?

To compare the dividend payouts of Beta Drugs Ltd and Zydus Lifesciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions